Any current/future new fundraising through debt or equity?

The company plans to utilize money raised from warrants in the next one year, which can partly be used to pay off short-term debt. Fund utilization will also focus on various initiatives beyond just debt repayment, including hospital expansion and operational improvements. There is no explicit mention of fresh fundraising through new debt or equity in the immediate future within the provided excerpts. Existing short-term borrowings have increased due to acquisitions and inter-company transactions, but no new fundraising rounds were detailed. Focus appears to be on constructive utilizat

Any current/future capex/capital investment/strategic investment?

Plans to invest in hospital expansion, specifically the Mumbai Khopoli Hospital: - Current bed capacity: 53 beds. - Future plan: Addition of 100 more beds within next 12 to 18 months, pending approval from MSRDC. Investment to improve hospital accommodation once approval is received. Acquisitions made: - UV Ayurgen (for in-house manufacturing of food products) to reduce purchase costs by 20%-30%. - Dynamic Remedies Private Limited (to manufacture medicines) to improve margins and product quality. Expansion plans include opening franchise hospitals where expenses are borne by franchisee

Future growth expectations in sales/revenue/volumes?

The company targets a 15% to 20% growth in topline (revenue) in the coming year. Expansion focus will be on hospitals, with plans to increase existing hospital capacity, which typically yield higher EBITDA margins than clinics. Clinic expansion will continue primarily through franchise models, reducing company investment and maintaining presence in local residential areas. Marketing budget is planned to increase from Rs. 14-15 crores to Rs. 18-20 crores to boost topline and attract more diseased patients. The new marketing strategy aims to target diseased patients (diabetes, heart cond

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a topline growth of approximately 15% to 20% in the coming year (FY25). Sustainable EBITDA margins are expected to improve from a conservative 10% to a target range of 15% to 20% over the next 3-5 years, with current efforts already underway to reduce expenses. Employee cost reductions and other cost control measures implemented will contribute to EBITDA margin improvement. Marketing expenses are planned to increase from around Rs. 14-15 crores to Rs. 18-20 crores to drive topline growth. Profit after tax weakened to Rs. 1.99 crores in FY24 but is expected to improv

Vaidya Sane Ayurved Laboratories LtdQ4 FY24Healthcare Equipment & Supplies

Vaidya Sane Ayurved Laboratories Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹136P/E: 15.9Market Cap: ₹143 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company targets a 15% to 20% growth in topline (revenue) in the coming year.
Expansion focus will be on hospitals, with plans to increase existing hospital capacity, which typically yield higher EBITDA margins than clinics.
Clinic expansion will continue primarily through franchise models, reducing company investment and maintaining presence in local residential areas.
Marketing budget is planned to increase from Rs. 14-15 crores to Rs. 18-20 crores to boost topline and attract more diseased patients.
The new marketing strategy aims to target diseased patients (diabetes, heart conditions) for higher ticket sizes and improved revenue.
Expect operational breakeven for new hospitals like Vizag within 6-7 months of opening.
Long-term clinic expansion to 1000 clinics delayed to 3-4 years timeframe, with a combination of online and offline presence expected.
Overall, sustainable EBITDA margins targeted between 15% and 20% driven by optimized cost structure and revenue growth.

Margin guidance

Category 1

The company targets a topline growth of approximately 15% to 20% in the coming year (FY25).
Sustainable EBITDA margins are expected to improve from a conservative 10% to a target range of 15% to 20% over the next 3-5 years, with current efforts already underway to reduce expenses.
Employee cost reductions and other cost control measures implemented will contribute to EBITDA margin improvement.
Marketing expenses are planned to increase from around Rs. 14-15 crores to Rs. 18-20 crores to drive topline growth.
Profit after tax weakened to Rs. 1.99 crores in FY24 but is expected to improve with revenue growth and margin expansion efforts.
EPS was Rs. 1.88 in FY24, with growth expected alongside improved profitability.
Expansion focus will be on hospital business, which has higher margins (20-30% EBITDA) compared to clinics (30-40% unallocated margins), supporting margin growth.

See what Vaidya Sane Ayurved Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company plans to utilize money raised from warrants in the next one year, which can partly be used to pay off short-term debt.
Fund utilization will also focus on various initiatives beyond just debt repayment, including hospital expansion and operational improvements.
There is no explicit mention of fresh fundraising through new debt or equity in the immediate future within the provided excerpts.
Existing short-term borrowings have increased due to acquisitions and inter-company transactions, but no new fundraising rounds were detailed.
Focus appears to be on constructive utilization of current cash reserves and funds raised via warrants to support growth and reduce debt.

Order book

The transcript provided does not mention any information regarding the current or expected order book or pending orders for Vaidya Sane Ayurved Laboratories Limited. The discussion primarily covers topics related to hospital expansion, marketing strategies, financials, acquisitions, clinic and hospital business models, and growth projections but does not provide specific details on order books or pending orders.

See what Vaidya Sane Ayurved Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Plans to invest in hospital expansion, specifically the Mumbai Khopoli Hospital:
- Current bed capacity: 53 beds.
- Future plan: Addition of 100 more beds within next 12 to 18 months, pending approval from MSRDC.
Investment to improve hospital accommodation once approval is received.
Acquisitions made:
- UV Ayurgen (for in-house manufacturing of food products) to reduce purchase costs by 20%-30%.
- Dynamic Remedies Private Limited (to manufacture medicines) to improve margins and product quality.
Expansion plans include opening franchise hospitals where expenses are borne by franchisees but revenue shares accrue to the company.
Marketing investment planned: Increasing marketing budget from Rs. 14-15 crores to Rs. 18-20 crores to boost top-line growth.

Track Vaidya Sane Ayurved Laboratories Ltd — get its next earnings analysis in your feed

How does Vaidya Sane Ayurved Laboratories Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisVaidya Sane Ayurved Laboratories Ltd

Rev 3Mar 1

See where Vaidya Sane Ayurved Laboratories Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Vaidya Sane Ayurved Laboratories Ltd rank in Healthcare Equipment & Supplies?

Compare Vaidya Sane Ayurved Laboratories Ltd against every Healthcare Equipment & Supplies company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Vaidya Sane Ayurved Laboratories Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →